Archive
Here you’ll find timely and relevant information about our company, including press, and social media channels focusing on the development of tropical disease medicines for malaria prevention and dengue fever treatment.
Events
ON-DEMAND WEBINAR: Plans for Further Development of ARAKODA® (tafenoquine)
Please join CEO Geoffrey Dow as he discusses future plans for testing of ARAKODA® (tafenoquine) for potential use in COVID-19 in light of recent in vitro study results.
March 6-7, 2017 – Zurich, CH
60P attends the 10th Annual European Life Sciences CEO Forum (ELSCEO) as a presenter and a partnering company.
March 2017 – Singapore & Shanghai
60P attends AusBiotech Series.
June 19-22, 2017 – San Diego, CA
60P attends International Bio as a presenting and partnering company.
Press
April 26, 2023
60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections
June 21, 2022
Positive Phase II Study Data for ARAKODA® (tafenoquine) in Patients with Mild-Moderate COVID-19 Disease Published by New Microbes and New Infections; Larger Studies Planned to Confirm ARAKODA Accelerates Clinical Recovery in Mild-Moderate COVID-19
December 15, 2021
Positive Phase II Study Data Suggest ARAKODA® (tafenoquine) Numerically Improved Clinical Recovery in Patients with Mild-Moderate COVID-19 Disease
November 19, 2021
ARAKODA® (tafenoquine) clinical safety, tolerability confirmed in long-term safety study; results published in Tropical Medicine and Infectious Disease
October 8, 2021
Data Safety Monitoring Board Recommends Completion of Phase II Study to Evaluate the Efficacy and Safety of ARAKODA® (tafenoquine) for Treatment of Mild-Moderate Covid-19 Disease
August 5, 2021
60 Degrees Pharmaceuticals Announces Completion of Long-Term Safety of ARAKODA® (tafenoquine) in Healthy Adult Volunteers
July 14, 2020
60 Degrees Pharmaceuticals Announces Positive Results of Cell Culture Testing of ARAKODA® (tafenoquine) for COVID-19
November 21, 2019
ARAKODA™ (tafenoquine) tablets, first prescription drug approved for malaria prevention by US FDA in over 18 years,
now available in US
March 20, 2019
60 Degrees Pharmaceuticals (60P) achieves first global product launch milestone
READ MORE
September 18, 2018
KODATEF® (tafenoquine) approved in Australia; first malaria prevention drug in more than two decades
READ MORE
August 27, 2018
Military scientists have discovered a new malaria drug that could help eradicate the disease — and it’s hitting shelves soon
READ MORE
August 9, 2018
U.S. Food and Drug Administration Approves ARAKODA™ (tafenoquine) tablets for oral use
READ MORE
July 26, 2018
U.S. FDA Advisory Committee votes in favor of Tafenoquine for the prevention of malaria
READ MORE
February 13, 2018 – Fort Detrick, MD
Priority Review Designation Received for Tafenoquine
READ MORE
February 7, 2018 – Washington DC
60P received Priority Review Designation from the USFDA for Tafenoquine (TQ) for prevention of malaria in adults
READ MORE
January 16, 2018
US Army Medical Research Lab Gets Fast Track Approval from USFDA for Malaria Drug
January 4, 2018
60 Degrees Pharmaceuticals Fast Tracked For Malaria Drug
READ MORE
December 18, 2017
60P Submits New Drug Application to USFDA for Antimalarial Drug Tafenoquine
READ MORE
May 16, 2017
60P’s investigational antimalarial agent tafenoquine is shown to be free of neurologic toxicity in adult rats according to recent study findings.
READ MORE
December 11, 2015
60P has received the first tranche of $4 million in a debt financing deal with Knight Therapeutics Inc. in support of our drug development program for tropical diseases.
READ MORE
August 31, 2015
60P has received approval to conduct a clinical study with celgosivir and modipafant in dengue patients in collaboration with Singapore General Hospital.
READ MORE
April 28, 2015
60P recently entered into a cooperative research and development agreement with the US Army to commercialize 60P003 (Tafenoquine) for malaria prophylaxis.
READ MORE
July 30, 2014
60P recently entered into an exclusive licensing deal with SingHealth and Duke-National University of Singapore Graduate Medical School to further develop celgosivir (60P001) for dengue fever.
June 11, 2014
One of 60P’s partners, Duke-NUS Medical School and its collaborators, completed a Phase I clinical study that demonstrated the safety of celgosivir in dengue patients and a trend toward faster NS1 clearance, suggesting the possibility of mitigating vascular permeability syndrome using glucosidase inhibitors.
READ MORE
April 1, 2014
60P has entered into a research collaboration agreement with the Duke-NUS Medical School to investigate the utility of different combinations of dengue drugs. Dengue, like other viral diseases, will likely require a combination of different host and virus-targeted molecules to achieve useful clinical benefit. Studies performed by Dr. Subhash Vasudevan.
January 1, 2014
60P established a subsidiary, 60P Australia, Pty. Ltd. 60P Australia will take the lead in continuing the company’s development of dengue therapeutics.
April 9, 2013
Report suggests that the incidence of dengue may have been underestimated by a factor of three. Therefore, prior estimates, including our own, of economic burden and the potential market for dengue drugs, will need to be revised upward.
READ MORE
September 8, 2012
60P estimates the potential market for dengue drugs to be $338 million annually. Published in Antiviral Research, the study was based on publicly available information regarding medical costs and lost productivity associated with clinical cases of dengue that result in an estimated economic burden of at least $1.7 billion a year.
READ MORE
627,000
Annual deaths from malaria globally
125,000,000
Travelers to malaria endemic regions per annum
390,000,000
Annual dengue infections globally
202-327-5422
1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036